America can either cede the future of biotechnology to our adversaries or summon the vision and resolve to lead it.

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.

Debut Biotech, a company innovating new molecules through advanced biotechnology, is partnering with Image Skincare to launch ...

John Crowley doesn’t worry about where his kids’ toys are made, but he told the Senate Health, Education, Labor and Pensions Committee that he does care where their medicines are made. His concerns, ...

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Duopharma Biotech Berhad (KLSE:DPHARMA) as an investment opportunity by projecting its future cash ...

Telangana government prioritizes biotechnology growth, emphasizing its vital role in healthcare and innovation at the IKMC ...

The U.S. has ceded its leadership in critical industries before. It must not do so with China and biotech now, writes the ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

A Bay Area biotech company is behind a potentially groundbreaking blood test that promises to be a game-changer in cancer ...

IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...